SecBot SecBot

INDP

Indaptus Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001857044 Biotech & Drug Discovery
$3.45 +0.28 (+8.83%)
Nov 16 4:00 PM ET · prev $3.17
Market cap
$483.8M
Small cap
Median target
$10.00
+190% · range $10.00–10.00
1 year
+52.0%
from $2.27 · Nov 17
30 days
+26.4%
from $2.73
52-week range
$0.9360–4.75
−27% from high · low Aug 18
Avg volume 20D
248.5K
shares / day
Short interest
1.14M
≈0.7% of shares · +33.0%
Days to cover
4.0
at average volume
Insider net
$0.00
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read BEARISH 11 reports · 90 days
Balance 5 bearish · 0 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 10/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsBULLISH

    Q3 2026: 6 added (0 new), 1 trimmed or exited.

  • Short sellersBUILDING

    Short interest +33.0% to 1.14M shares. 4.0 days to cover, ≈0.7% of shares.

  • TrendUPTREND

    15% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCDOUBLED195,620$449.9K
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED135,978$312.7K
JANE STREET GROUP, LLCADD86,484$198.9K
UBS Group AGDOUBLED83,363$191.7K
VANGUARD FIDUCIARY TRUST CODOUBLED65,315$150.2K
MORGAN STANLEYNEAR_EXIT1,263$2.9K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED56,470$169.4K
MORGAN STANLEYDOUBLED8,936$26.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Nov 2024
12-month targets · 1 analysts

Price is below the lowest target. Median implies +190%.Targets as of Apr 28, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2024Maxim Group
MAINTAIN
MAINTAINBuy
Oct 16, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 17, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 15, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 20, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 15, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$0
sold · 1 insider
DateInsiderTypeValue
Mar 23, 2026
Lazar David E.
Director
Mar 23, 2026
SELL196,800 sh
Mar 23, 2026
Lazar David E.
Director
Mar 23, 2026
SELL700,000 sh
Feb 26, 2026
Jabbour Jerome D
Director
Feb 26, 2026
AWARD25,000 sh
Feb 11, 2026
Meckler Jeffrey A
Co-Chief Executive Officer
Feb 11, 2026
AWARD12,136 sh
Feb 11, 2026
Meckler Jeffrey A
Co-Chief Executive Officer
Feb 11, 2026
TO ISSUER3,033 sh
Feb 11, 2026
Meckler Jeffrey A
Co-Chief Executive Officer
Feb 11, 2026
TO ISSUER12,136 sh
Feb 11, 2026
Meckler Jeffrey A
Co-Chief Executive Officer
Feb 11, 2026
AWARD1,519 sh
Feb 11, 2026
Meckler Jeffrey A
Co-Chief Executive Officer
Feb 11, 2026
AWARD3,033 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$0.00
Next QNoneNoneNo data$0.00
Current FYNoneNoneNo data$0.00
Next FYNoneNoneNo data$0.00

Short side

FINRA· Oct 30, 2026
1,139,319
shares short
+33.0%
vs prior settlement
4.0
days to cover
≈0.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Indaptus Therapeutics reported Q3 2026 net loss of $1.0M ($0.01 per share), narrowed from $3.0M ($2.98) a year ago…
PRESS-RELEASE · Impact 4/10
Nov 13, 2026 Earnings
Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” o
Oct 22, 2026 SEC
Sino Lion Ventures Ltd and Chenhao Xu filed Amendment No. 3 to their Schedule 13D, reporting a decrease in beneficial…
SC 13D/A · Impact 4/10
Oct 22, 2026 SEC
Junyi Dai, CEO and Chairman of Indaptus Therapeutics, filed Amendment No. 3 to Schedule 13D reporting a passive…
SC 13D/A · Impact 3/10
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · DOUBLED
195,620 shares ($449.9K)
Sep 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC · DOUBLED
135,978 shares ($312.7K)
Mar 23, 2026 Insider
Lazar David E. sold 196,800 shares
Director
Mar 23, 2026 Insider
Lazar David E. sold 700,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

20 filings · 0 bullish · 11 bearish · 9 neutral
All INDP filing & press-release reports (20)